Kim Jee Min, Park Eu Gene, Lee Joo Young, Kim Young Hoon, Kim Yeji, Kim Hwan Soo, Kim Yejin, Han Ji Yoon, Han Seung Beom
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Pediatrics, College of Medicine, Hallym University, Chuncheon, Republic of Korea.
Transl Pediatr. 2023 May 30;12(5):807-815. doi: 10.21037/tp-22-579. Epub 2023 Apr 27.
While the pandemic of coronavirus disease 2019 (COVID-19) is ongoing, the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been dominant recently. The Omicron variant causes more seizures in pediatric patients compared with previously circulated variants. This study aimed to investigate the incidence and clinical features of febrile seizure (FS) in pediatric patients with COVID-19 during the Omicron era.
The medical records of pediatric patients (≤18 years of age) diagnosed with COVID-19, who presented with FS between February 2020 and June 2022, were reviewed retrospectively to analyze clinical characteristics of FS in seven university-affiliated hospitals of Korea.
Of 664 pediatric patients with COVID-19 during the study period, 46 during the pre-Omicron period and 589 during the Omicron period were included in the study analysis; 29 patients during the transition period were excluded. Among the included patients, 81 (12.8%) had concomitant FS, and most (76.5%) experienced simple FS. All FS episodes occurred during the Omicron period and none of them during pre-Omicron period (P=0.016). Sixty-five (80.2%) and 16 (19.8%) patients were categorized as FS (patient age ≤60 months) and late-onset FS (patient age >60 months), respectively. Underlying neurologic disease (P=0.013) and focal onset seizure (P=0.012) were more common in the late-onset FS group than in the FS group; however, overall clinical manifestations and outcomes including seizures consistent with characteristics of complex FS and subsequent epilepsy were similar between the two groups.
As the COVID-19 pandemic persists, the incidence of FS has increased with the emergence of the Omicron variant. About one-fifth of the patients experiencing FS due to infection by the Omicron variant of SARS-CoV-2 were aged >60 months; however, clinical characteristics and outcomes were favorable. More information and long-term prognoses in patients with FS due to COVID-19 should be acquired.
在2019冠状病毒病(COVID-19)大流行期间,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的奥密克戎变异株最近占据主导地位。与先前传播的变异株相比,奥密克戎变异株在儿科患者中引发更多癫痫发作。本研究旨在调查奥密克戎时代COVID-19儿科患者热性惊厥(FS)的发病率及临床特征。
回顾性分析2020年2月至2022年6月期间在韩国七家大学附属医院诊断为COVID-19且出现FS的儿科患者(≤18岁)的病历,以分析FS的临床特征。
在研究期间的664例COVID-19儿科患者中,46例处于奥密克戎变异株出现之前的时期,589例处于奥密克戎变异株时期,研究分析纳入了这些病例;29例处于过渡期的患者被排除。在纳入的患者中,81例(12.8%)伴有FS,其中大多数(76.5%)经历的是单纯性FS。所有FS发作均发生在奥密克戎变异株时期,在奥密克戎变异株出现之前的时期均未发生(P=0.016)。65例(80.2%)和16例(19.8%)患者分别被归类为FS(患者年龄≤60个月)和迟发性FS(患者年龄>60个月)。迟发性FS组潜在神经系统疾病(P=0.013)和局灶性发作(P=0.012)比FS组更常见;然而,两组之间包括与复杂性FS特征相符的癫痫发作及后续癫痫在内的总体临床表现和结局相似。
随着COVID-19大流行持续,随着奥密克戎变异株的出现,FS的发病率有所增加。因感染SARS-CoV-2奥密克戎变异株而出现FS的患者中约五分之一年龄>60个月;然而,临床特征和结局良好。应获取更多关于COVID-19所致FS患者的信息及长期预后情况。